The Top 5 Biosimilars Articles for the Week of June 3

June 7, 2019

The Center for Biosimilars® recaps the top stories for the week of June 3, 2019.

Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of June 3.

Number 5: Prestige BioPharma announced that the European Medicines Agency will review its application for a proposed trastuzumab biosimilar, HD201.

Number 4: During this week’s 2019 American Society of Clinical Oncology Annual Meeting (ASCO), researchers presented the final overall survival results from the phase 3 HERITAGE study of biosimilar trastuzumab, Ogivri.

Number 3: Also at ASCO, Samsung Bioepis presented long-awaited 3-year results for its biosimilar trastuzumab, Ontruzant.

Number 2: With patents on reference products that treat multiple sclerosis set to expire soon in Latin America, a panel of experts published a set of recommendations on biosimilars in the region.

Number 1: Ahead of the anticipated 2019 marketing of FDA-approved anticancer biosimilars in the United States, a pharmacy benefit manager is launching an oncology biosimilar program.

Finally, last week, our e-newsletter asked whether you think other states will follow Colorado’s lead in capping patients’ costs for insulin.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.